Current treatment options for vulvovaginal atrophy

Rebekah Burich, Michael Degregorio

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Vulvovaginal atrophy (VVA), a condition associated with declining estrogen levels, is commonly seen in postmenopausal women. VVA is marked by vaginal dryness, itching, dyspareunia and incontinence, which can contribute to diminishing quality of life for millions of postmenopausal women worldwide. Most available treatments contain estrogen, whether administered locally or systemically. Other treatment options include lubricants and moisturizers. These therapeutic approaches can provide temporary relief of some VVA symptoms while on therapy, but do not address the underlying condition, and they are not without potential side effects. However, promising new VVA therapies are in development that target the underlying condition with acceptable side-effect profiles. In this article, the benefits and drawbacks of current therapies and new treatments under development for VVA are discussed.

Original languageEnglish (US)
Pages (from-to)141-151
Number of pages11
JournalExpert Review of Obstetrics and Gynecology
Volume6
Issue number2
DOIs
StatePublished - Mar 2011

Fingerprint

Atrophy
Therapeutics
Estrogens
Dyspareunia
Lubricants
Pruritus
Quality of Life

Keywords

  • atrophic vaginitis
  • dyspareunia
  • vulvovaginal atrophy

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Reproductive Medicine
  • Maternity and Midwifery
  • Pediatrics, Perinatology, and Child Health

Cite this

Current treatment options for vulvovaginal atrophy. / Burich, Rebekah; Degregorio, Michael.

In: Expert Review of Obstetrics and Gynecology, Vol. 6, No. 2, 03.2011, p. 141-151.

Research output: Contribution to journalArticle

Burich, Rebekah ; Degregorio, Michael. / Current treatment options for vulvovaginal atrophy. In: Expert Review of Obstetrics and Gynecology. 2011 ; Vol. 6, No. 2. pp. 141-151.
@article{7d23864f0a5a4920a094a560aefb7ea8,
title = "Current treatment options for vulvovaginal atrophy",
abstract = "Vulvovaginal atrophy (VVA), a condition associated with declining estrogen levels, is commonly seen in postmenopausal women. VVA is marked by vaginal dryness, itching, dyspareunia and incontinence, which can contribute to diminishing quality of life for millions of postmenopausal women worldwide. Most available treatments contain estrogen, whether administered locally or systemically. Other treatment options include lubricants and moisturizers. These therapeutic approaches can provide temporary relief of some VVA symptoms while on therapy, but do not address the underlying condition, and they are not without potential side effects. However, promising new VVA therapies are in development that target the underlying condition with acceptable side-effect profiles. In this article, the benefits and drawbacks of current therapies and new treatments under development for VVA are discussed.",
keywords = "atrophic vaginitis, dyspareunia, vulvovaginal atrophy",
author = "Rebekah Burich and Michael Degregorio",
year = "2011",
month = "3",
doi = "10.1586/eog.11.3",
language = "English (US)",
volume = "6",
pages = "141--151",
journal = "Expert Review of Obstetrics and Gynecology",
issn = "1747-4108",
publisher = "Expert Reviews Ltd.",
number = "2",

}

TY - JOUR

T1 - Current treatment options for vulvovaginal atrophy

AU - Burich, Rebekah

AU - Degregorio, Michael

PY - 2011/3

Y1 - 2011/3

N2 - Vulvovaginal atrophy (VVA), a condition associated with declining estrogen levels, is commonly seen in postmenopausal women. VVA is marked by vaginal dryness, itching, dyspareunia and incontinence, which can contribute to diminishing quality of life for millions of postmenopausal women worldwide. Most available treatments contain estrogen, whether administered locally or systemically. Other treatment options include lubricants and moisturizers. These therapeutic approaches can provide temporary relief of some VVA symptoms while on therapy, but do not address the underlying condition, and they are not without potential side effects. However, promising new VVA therapies are in development that target the underlying condition with acceptable side-effect profiles. In this article, the benefits and drawbacks of current therapies and new treatments under development for VVA are discussed.

AB - Vulvovaginal atrophy (VVA), a condition associated with declining estrogen levels, is commonly seen in postmenopausal women. VVA is marked by vaginal dryness, itching, dyspareunia and incontinence, which can contribute to diminishing quality of life for millions of postmenopausal women worldwide. Most available treatments contain estrogen, whether administered locally or systemically. Other treatment options include lubricants and moisturizers. These therapeutic approaches can provide temporary relief of some VVA symptoms while on therapy, but do not address the underlying condition, and they are not without potential side effects. However, promising new VVA therapies are in development that target the underlying condition with acceptable side-effect profiles. In this article, the benefits and drawbacks of current therapies and new treatments under development for VVA are discussed.

KW - atrophic vaginitis

KW - dyspareunia

KW - vulvovaginal atrophy

UR - http://www.scopus.com/inward/record.url?scp=79952959860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952959860&partnerID=8YFLogxK

U2 - 10.1586/eog.11.3

DO - 10.1586/eog.11.3

M3 - Article

VL - 6

SP - 141

EP - 151

JO - Expert Review of Obstetrics and Gynecology

JF - Expert Review of Obstetrics and Gynecology

SN - 1747-4108

IS - 2

ER -